Virazole

Virazole is a synthetic nucleoside antiviral drug. It is administered as a continuous aerosol utilizing a specialized Small Particle Aerosol Generator (SPAG-2) unit. It is indicated only for severe, hospitalized cases of RSV in pediatric patients.

Dosage by Body Weight

The recommended treatment is a continuous aerosol administration of a 20 mg/mL solution of Virazole (6 grams reconstituted in 300 mL of sterile water) for 12 to 18 hours per day for 3 to 7 days. Dosing is determined by aerosol concentration and duration of exposure, not by patient body weight.

Body Weight
Below 5 kg
Dose
20 mg/mL aerosol concentration
Frequency
Continuous inhalation for 12-18 hours daily
Tracking Notes
Dosing is based on constant aerosol concentration via SPAG-2 nebulizer, not body weight. Treatment is typically for 3 to 7 days.
Body Weight
5-7 kg
Dose
20 mg/mL aerosol concentration
Frequency
Continuous inhalation for 12-18 hours daily
Tracking Notes
Dosing is based on constant aerosol concentration via SPAG-2 nebulizer, not body weight. Treatment is typically for 3 to 7 days.
Body Weight
8-10 kg
Dose
20 mg/mL aerosol concentration
Frequency
Continuous inhalation for 12-18 hours daily
Tracking Notes
Dosing is based on constant aerosol concentration via SPAG-2 nebulizer, not body weight. Treatment is typically for 3 to 7 days.
Body Weight
11-15 kg
Dose
20 mg/mL aerosol concentration
Frequency
Continuous inhalation for 12-18 hours daily
Tracking Notes
Dosing is based on constant aerosol concentration via SPAG-2 nebulizer, not body weight. Treatment is typically for 3 to 7 days.
Body Weight
16-20 kg
Dose
20 mg/mL aerosol concentration
Frequency
Continuous inhalation for 12-18 hours daily
Tracking Notes
Dosing is based on constant aerosol concentration via SPAG-2 nebulizer, not body weight. Treatment is typically for 3 to 7 days.

Weight-based dosage tracking table for Virazole, including body weight, dose, frequency, and tracking notes.
Body Weight	Dose	Frequency	Tracking Notes
Below 5 kg	20 mg/mL aerosol concentration	Continuous inhalation for 12-18 hours daily	Dosing is based on constant aerosol concentration via SPAG-2 nebulizer, not body weight. Treatment is typically for 3 to 7 days.
5-7 kg	20 mg/mL aerosol concentration	Continuous inhalation for 12-18 hours daily	Dosing is based on constant aerosol concentration via SPAG-2 nebulizer, not body weight. Treatment is typically for 3 to 7 days.
8-10 kg	20 mg/mL aerosol concentration	Continuous inhalation for 12-18 hours daily	Dosing is based on constant aerosol concentration via SPAG-2 nebulizer, not body weight. Treatment is typically for 3 to 7 days.
11-15 kg	20 mg/mL aerosol concentration	Continuous inhalation for 12-18 hours daily	Dosing is based on constant aerosol concentration via SPAG-2 nebulizer, not body weight. Treatment is typically for 3 to 7 days.
16-20 kg	20 mg/mL aerosol concentration	Continuous inhalation for 12-18 hours daily	Dosing is based on constant aerosol concentration via SPAG-2 nebulizer, not body weight. Treatment is typically for 3 to 7 days.

Formulation

Powder for Inhalation Solution

Purpose

Treatment of hospitalized infants and young children with severe lower respiratory tract infections caused by respiratory syncytial virus (RSV).

Generic Name

Ribavirin

Scheduled Drug

No. This medicine is generally not treated as a scheduled/prescription-only drug in common consumer references, but local rules may vary.

Alternatives

Ribavirin Inhalation Solution (generic)